{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:33:27Z","timestamp":1793784807275,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32100513"],"award-info":[{"award-number":["32100513"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Science and Technology Program of Guangzhou, China","award":["2024A04J3341"],"award-info":[{"award-number":["2024A04J3341"]}]},{"name":"Basic and Applied Basic Research Foundation of Guangzhou, China","award":["SL2023A04J00291"],"award-info":[{"award-number":["SL2023A04J00291"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>MAPK\/ERK1\/2 signaling is often activated in hepatocellular carcinoma (HCC), yet classical RAS-RAF-MEK mutations are rare, indicating the involvement of non-canonical regulatory mechanisms. Long non-coding RNAs (lncRNAs) can encode microproteins that play key roles in cancer. LncRNA <jats:italic>ASH1L-AS1<\/jats:italic> has coding potential, but its role in HCC remains unclear. Clarifying its role in MAPK signaling may uncover novel therapeutic targets for HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Translatable lncRNAs associated with HCC were identified by integrating data from the TCGA-LIHC cohort and the TransLnc database. The functional role of <jats:italic>ASH1L-AS1<\/jats:italic> and its encoded microprotein APPLE was explored through in vitro and in vivo assays, such as CCK-8, EdU incorporation, wound healing, Transwell migration and invasion, and xenograft tumor models. Mechanistic investigations were conducted to elucidate molecular mechanisms and identify potential therapeutic strategies, including co-immunoprecipitation, mass spectrometry, ChIP-qPCR, luciferase reporter assays, truncation mutation analysis, immunofluorescence, Western blot, RNA sequencing, drug sensitivity analysis etc.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 696 translatable lncRNAs associated with HCC were identified, with their encoded products exhibiting specific subcellular localization. Among them, <jats:italic>ASH1L-AS1<\/jats:italic> stood out due to strong translational evidence and its significant association with disease progression, poor prognosis, immunosuppressive tumor microenvironment, and estrogen signaling. We confirmed that <jats:italic>ASH1L-AS1<\/jats:italic> encodes a microprotein, APPLE, which is stably expressed in HCC cells and consistently upregulated in tumor tissues regardless of RAS mutation status. Functionally, APPLE promotes ERK1\/2 phosphorylation, activates MAPK signaling, and enhances HCC cell proliferation, migration, invasion, and tumor growth\u2014effects reversed by APPLE knockdown or ERK1\/2 inhibition. Mechanistically, APPLE binds to ERK1\/2 and phosphatases PP1\/PP2A, preventing ERK1\/2 dephosphorylation and sustaining MAPK pathway activation. Additionally, the transcription factor E2F1 directly binds to the <jats:italic>ASH1L-AS1<\/jats:italic> promoter (\u2212\u2009300 to \u2212\u2009290\u00a0bp), upregulating APPLE expression and further amplifying ERK1\/2 signaling. Drug sensitivity analysis identified 220 treatment combinations potentially effective against HCC subtypes driven by hyperactivation of the E2F1\u2013ASH1L-AS1\/APPLE\u2013ERK1\/2 axis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study characterized APPLE as a novel oncogenic microprotein encoded by lncRNA <jats:italic>ASH1L-AS1<\/jats:italic>, uncovering a non-canonical mechanism of MAPK activation in HCC. The identified E2F1\u2013ASH1L-AS1\/APPLE\u2013ERK1\/2 signaling axis provides new insights into HCC pathogenesis and represents a promising target for precision therapy, though further validation in clinical cohorts and preclinical studies is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03465-w","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T03:49:23Z","timestamp":1752205763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1\/PP2A-mediated ERK1\/2 dephosphorylation in hepatocellular carcinoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"6","key":"3465_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"issue":"3","key":"3465_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3465_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the L","year":"2025","unstructured":"European Association for the Study of the L. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"1","key":"3465_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-020-01188-4","volume":"19","author":"Z Huang","year":"2020","unstructured":"Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):77.","journal-title":"Mol Cancer"},{"issue":"5","key":"3465_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","volume":"179","author":"FJ Slack","year":"2019","unstructured":"Slack FJ, Chinnaiyan AM. The role of Non-coding RNAs in oncology. Cell. 2019;179(5):1033\u201355.","journal-title":"Cell"},{"issue":"3","key":"3465_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41422-024-01059-3","volume":"35","author":"C Shi","year":"2025","unstructured":"Shi C, Liu F, Su X, Yang Z, Wang Y, Xie S, et al. Comprehensive discovery and functional characterization of the noncanonical proteome. Cell Res. 2025;35(3):186\u2013204.","journal-title":"Cell Res"},{"issue":"2","key":"3465_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.tig.2024.09.003","volume":"41","author":"E Kina","year":"2025","unstructured":"Kina E, Larouche JD, Thibault P, Perreault C. The cryptic immunopeptidome in health and disease. Trends Genet. 2025;41(2):162\u20139.","journal-title":"Trends Genet"},{"issue":"28","key":"3465_CR8","doi-asserted-by":"publisher","first-page":"eadn3628","DOI":"10.1126\/sciadv.adn3628","volume":"10","author":"ME Camarena","year":"2024","unstructured":"Camarena ME, Theunissen P, Ruiz M, Ruiz-Orera J, Calvo-Serra B, Castelo R, et al. Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort. Sci Adv. 2024;10(28):eadn3628.","journal-title":"Sci Adv"},{"key":"3465_CR9","doi-asserted-by":"crossref","unstructured":"Zheng C, Wei Y, Zhang P, Xu L, Zhang Z, Lin K et al. CRISPR\/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. J Clin Invest 2023; 133(5).","DOI":"10.1172\/JCI159940"},{"key":"3465_CR10","doi-asserted-by":"crossref","unstructured":"Zhang Q, Liu L. Novel insights into small open reading frame-encoded micropeptides in hepatocellular carcinoma: A potential breakthrough. Cancer Lett 2024; 587(216691.","DOI":"10.1016\/j.canlet.2024.216691"},{"issue":"3","key":"3465_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.tcb.2021.10.010","volume":"32","author":"BW Wright","year":"2022","unstructured":"Wright BW, Yi Z, Weissman JS, Chen J. The dark proteome: translation from noncanonical open reading frames. Trends Cell Biol. 2022;32(3):243\u201358.","journal-title":"Trends Cell Biol"},{"issue":"21","key":"3465_CR12","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1016\/j.molcel.2021.08.033","volume":"81","author":"L Sun","year":"2021","unstructured":"Sun L, Wang W, Han C, Huang W, Sun Y, Fang K, et al. The oncomicropeptide APPLE promotes hematopoietic malignancy by enhancing translation initiation. Mol Cell. 2021;81(21):4493\u2013508. e9.","journal-title":"Mol Cell"},{"issue":"46","key":"3465_CR13","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1038\/s41388-023-02855-8","volume":"42","author":"M Xie","year":"2023","unstructured":"Xie M, Zhang L, Han L, Huang L, Huang Y, Yang M, et al. The ASH1L-AS1-ASH1L axis controls NME1-mediated activation of the RAS signaling in gastric cancer. Oncogene. 2023;42(46):3435\u201345.","journal-title":"Oncogene"},{"issue":"1","key":"3465_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3465_CR15","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1002\/mco2.474","volume":"5","author":"X Luo","year":"2024","unstructured":"Luo X, He X, Zhang X, Zhao X, Zhang Y, Shi Y, et al. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm (2020). 2024;5(2):e474.","journal-title":"MedComm (2020)"},{"key":"3465_CR16","doi-asserted-by":"crossref","unstructured":"Moon H, Ro SW. MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel) 2021; 13(12).","DOI":"10.3390\/cancers13123026"},{"issue":"5","key":"3465_CR17","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jhep.2020.05.028","volume":"73","author":"Y Pang","year":"2020","unstructured":"Pang Y, Liu Z, Han H, Wang B, Li W, Mao C, et al. Peptide SMIM30 promotes HCC development by inducing SRC\/YES1 membrane anchoring and MAPK pathway activation. J Hepatol. 2020;73(5):1155\u201369.","journal-title":"J Hepatol"},{"issue":"1","key":"3465_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12943-022-01654-1","volume":"21","author":"M Li","year":"2022","unstructured":"Li M, Liu G, Jin X, Guo H, Setrerrahmane S, Xu X, et al. Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG\/EGFR signaling in renal cell carcinoma. Mol Cancer. 2022;21(1):181.","journal-title":"Mol Cancer"},{"issue":"1","key":"3465_CR19","doi-asserted-by":"publisher","first-page":"zcac002","DOI":"10.1093\/narcan\/zcac002","volume":"4","author":"SL Tinsley","year":"2022","unstructured":"Tinsley SL, Allen-Petersen BL. PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen. NAR Cancer. 2022;4(1):zcac002.","journal-title":"NAR Cancer"},{"issue":"1","key":"3465_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bbamcr.2018.07.006","volume":"1866","author":"PP Ruvolo","year":"2019","unstructured":"Ruvolo PP. Role of protein phosphatases in the cancer microenvironment. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):144\u201352.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"4","key":"3465_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/sj.emboj.7600980","volume":"25","author":"C Letourneux","year":"2006","unstructured":"Letourneux C, Rocher G, Porteu F. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J. 2006;25(4):727\u201338.","journal-title":"EMBO J"},{"issue":"44","key":"3465_CR22","doi-asserted-by":"publisher","first-page":"27205","DOI":"10.1074\/jbc.271.44.27205","volume":"271","author":"M Muda","year":"1996","unstructured":"Muda M, Theodosiou A, Rodrigues N, Boschert U, Camps M, Gillieron C, et al. The dual specificity phosphatases M3\/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. J Biol Chem. 1996;271(44):27205\u20138.","journal-title":"J Biol Chem"},{"issue":"11","key":"3465_CR23","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1074\/jbc.271.11.6497","volume":"271","author":"Y Chu","year":"1996","unstructured":"Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 Sevenmaker mutation. J Biol Chem. 1996;271(11):6497\u2013501.","journal-title":"J Biol Chem"},{"issue":"W1","key":"3465_CR24","doi-asserted-by":"publisher","first-page":"W228","DOI":"10.1093\/nar\/gkac278","volume":"50","author":"V Thumuluri","year":"2022","unstructured":"Thumuluri V, Almagro Armenteros JJ, Johansen AR, Nielsen H, Winther O. DeepLoc 2.0: multi-label subcellular localization prediction using protein Language models. Nucleic Acids Res. 2022;50(W1):W228\u201334.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3465_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"key":"3465_CR26","doi-asserted-by":"crossref","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013; 14(7).","DOI":"10.1186\/1471-2105-14-7"},{"key":"3465_CR27","doi-asserted-by":"crossref","unstructured":"Maeser D, Gruener RF, Huang RS. OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform 2021; 22(6).","DOI":"10.1093\/bib\/bbab260"},{"issue":"2","key":"3465_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109\u201316.","journal-title":"Nat Chem Biol"},{"issue":"D1","key":"3465_CR29","doi-asserted-by":"publisher","first-page":"D413","DOI":"10.1093\/nar\/gkab847","volume":"50","author":"D Lv","year":"2022","unstructured":"Lv D, Chang Z, Cai Y, Li J, Wang L, Jiang Q, et al. TransLnc: a comprehensive resource for translatable LncRNAs extends immunopeptidome. Nucleic Acids Res. 2022;50(D1):D413\u201320.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3465_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41587-020-00806-2","volume":"39","author":"JR Prensner","year":"2021","unstructured":"Prensner JR, Enache OM, Luria V, Krug K, Clauser KR, Dempster JM, et al. Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nat Biotechnol. 2021;39(6):697\u2013704.","journal-title":"Nat Biotechnol"},{"key":"3465_CR31","doi-asserted-by":"crossref","unstructured":"O\u2019Brien MH, Pitot HC, Chung SH, Lambert PF, Drinkwater NR, Bilger A. Estrogen Receptor-alpha suppresses liver carcinogenesis and establishes Sex-Specific gene expression. Cancers (Basel) 2021; 13(10).","DOI":"10.3390\/cancers13102355"},{"issue":"5","key":"3465_CR32","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1007\/s10528-023-10636-x","volume":"62","author":"Z Jie","year":"2024","unstructured":"Jie Z, Hongkun J, Shi Y, Fengxun Y, Xin L, Yijun M, et al. The influence of ESR2 gene polymorphisms on susceptibility to hepatitis B Virus-Related chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Biochem Genet. 2024;62(5):3946\u201360.","journal-title":"Biochem Genet"},{"issue":"23","key":"3465_CR33","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res. 2023;83(23):3861\u20137.","journal-title":"Cancer Res"},{"issue":"12","key":"3465_CR34","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarro LM, Bradshaw CR, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424\u201335.","journal-title":"Nat Med"},{"issue":"2","key":"3465_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/bioinformatics\/18.2.333","volume":"18","author":"X Messeguer","year":"2002","unstructured":"Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18(2):333\u20134.","journal-title":"Bioinformatics"},{"issue":"4","key":"3465_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41573-022-00618-w","volume":"22","author":"SM Stanford","year":"2023","unstructured":"Stanford SM, Bottini N. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders. Nat Rev Drug Discov. 2023;22(4):273\u201394.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"3465_CR37","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K, Metastasis. Cell. 2023;186(8):1564\u201379.","journal-title":"Cell"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03465-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03465-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03465-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:56:40Z","timestamp":1757221000000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03465-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03465-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and received informed consent from all human subjects. The Ethics Committee of Guangzhou Medical University approved the ethics statements for human subjects in this study (No.: 202412026). All animal experiments were performed according to the Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangzhou Medical University (No: GB2024-003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publication of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}